Ginkgo Bioworks Holdings, Inc. SEC filings DNA
Ginkgo Bioworks Holdings, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Jun 14, 2023. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Feb 26, 2026 | — |
| 424B5 | Prospectus supplement | Sep 4, 2025 | — |
| S-3 | Shelf registration | Aug 7, 2025 | — |
| S-8 | Employee stock plan registration | Feb 25, 2025 | — |
| 424B3 | Prospectus | May 17, 2024 | — |
| S-3 | Shelf registration | May 9, 2024 | — |
| S-8 | Employee stock plan registration | Mar 1, 2024 | — |
| 424B3 | Prospectus | Aug 29, 2023 | — |
| S-3 | Shelf registration | Aug 23, 2023 | — |
Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- DNA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1830214
- Former names
- Soaring Eagle Acquisition Corp. (until Sep 17, 2021); Spinning Eagle Acquisition Corp. (until Jan 4, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.